Evotec OAI to expand agreement with Oxford Bioscience Partners
Evotec OAI and Oxford Bioscience Partners (OBP), a life sciences venture capital firm based in Boston in the US, have expanded their 2002 agreement by integrating Evotec OAI's newly established rational drug design platform, EVOrationale.
Evotec OAI and Oxford Bioscience Partners (OBP), a life sciences venture capital firm based in Boston in the US, have expanded their 2002 agreement by integrating Evotec OAI's newly established rational drug design platform, EVOrationale.
Evotec OAI has recently built up its EVOrationale platform, consisting of protein engineering and production, X-ray crystallography and computational chemistry to assist its customers in delivering de novo structure determination, validation of screening hits and structure guided lead optimisation programmes. Over the past months, Evotec OAI has successfully applied the new platform to a range of targets including kinases, GPCRs, proteases, enzymes and more complex protein-ligand interactions.
'Evotec OAI has a long-standing track record in developing knowledge-driven drug discovery solutions,' said Bernard Questier, chief business officer. 'With the recent build-up of our computational chemistry capabilities, including a database of more than 5.5 million compounds for virtual screening purposes and a dedicated structural biology group, we are uniquely positioned to offer high quality, high speed integrated structure-guided drug discovery programmes to our partners.'